These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir. Rao S; Lungu C; Crespo R; Steijaert TH; Gorska A; Palstra RJ; Prins HAB; van Ijcken W; Mueller YM; van Kampen JJA; Verbon A; Katsikis PD; Boucher CAB; Rokx C; Gruters RA; Mahmoudi T Nat Commun; 2021 Apr; 12(1):2475. PubMed ID: 33931637 [TBL] [Abstract][Full Text] [Related]
27. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco. Bakhouch K; Oulad-Lahcen A; Bensghir R; Blaghen M; Elfilali KM; Ezzikouri S; Abidi O; Hassar M; Wakrim L J Infect Dev Ctries; 2009 Jun; 3(5):380-91. PubMed ID: 19759509 [TBL] [Abstract][Full Text] [Related]
28. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents. Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644 [TBL] [Abstract][Full Text] [Related]
29. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. Romano L; Venturi G; Giomi S; Pippi L; Valensin PE; Zazzi M J Med Virol; 2002 Feb; 66(2):143-50. PubMed ID: 11782921 [TBL] [Abstract][Full Text] [Related]
30. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466 [TBL] [Abstract][Full Text] [Related]
31. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407 [TBL] [Abstract][Full Text] [Related]
32. Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. Santoro MM; Svicher V; Gori C; Zaccarelli M; Tozzi V; Forbici F; D'Arrigo R; Trotta MP; Bellocchi MC; Visco-Comandini U; Cenci A; Bertoli A; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F New Microbiol; 2006 Apr; 29(2):89-100. PubMed ID: 16841549 [TBL] [Abstract][Full Text] [Related]
33. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Shan L; Deng K; Shroff NS; Durand CM; Rabi SA; Yang HC; Zhang H; Margolick JB; Blankson JN; Siliciano RF Immunity; 2012 Mar; 36(3):491-501. PubMed ID: 22406268 [TBL] [Abstract][Full Text] [Related]
34. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors. Banga R; Procopio FA; Cavassini M; Perreau M J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693 [TBL] [Abstract][Full Text] [Related]
35. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608 [TBL] [Abstract][Full Text] [Related]
36. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. Anta L; Blanco JL; Llibre JM; García F; Pérez-Elías MJ; Aguilera A; Pérez-Romero P; Caballero E; Vidal C; Cañizares A; Gutiérrez F; Dalmau D; Iribarren JA; Soriano V; de Mendoza C; J Antimicrob Chemother; 2013 Sep; 68(9):1994-2002. PubMed ID: 23629015 [TBL] [Abstract][Full Text] [Related]